Journal article icon

Journal article

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.

Abstract:

Reversible acetylation is mediated by histone deacetylase (HDAC), which is involved in regulating a broad repertoire of physiological processes, many of which are under aberrant control in tumor cells. Inhibition of HDAC activity prompts tumor cells to enter apoptosis; therefore, the utility of HDAC inhibitors for the treatment of cancer has been investigated and several HDAC inhibitors have now entered clinical trials. Although the clinical picture is evolving and the precise clinical utilit...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/ncponc1238

Authors


Journal:
Nature clinical practice. Oncology
Volume:
5
Issue:
12
Pages:
714-726
Publication date:
2008-12-05
DOI:
EISSN:
1743-4262
ISSN:
1743-4254
URN:
uuid:e2e8f5be-afce-4a67-8de0-9c082e23f784
Source identifiers:
264932
Local pid:
pubs:264932

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP